Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Itoh-Nakadai A, Liang M, Shindo M, Bibi C, Tomizawa-Murasawa M, Fujiki S, Kaneko A, Kanamaru E, Hashimoto M, Kajita H, Ando Y, Kojima M, Moody J, Iwasaki M, Takagi S, Nakagawa R, Agrawal S, Amitani-Iijima H, Sato K, Sorimachi Y, Suzuki N, Fukami T, Hanada K, Morita S, Katsura K, Matsumoto T, Kobayashi M, Kato M, Negishi Y, Shirouzu M, Najima Y, Takubo K, Hon CC, Uchida N, Taniguchi S, Momozawa Y, Carninci P, Shultz LD, Saito Y, de Hoon M, Shin JW, Ishikawa F. CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting. Nat Commun. 2026 Jan 26; 17(1):101.
-
Kim J, Shin DW, Lee J, Lee MJ, Yu YG, Lee DH, Kang TH. Engineering Native-like GPCR Antigens Enables Discovery of an LPA2-Blocking Antibody for Ovarian Cancer. ACS Synth Biol. 2026 Jan 16; 15(1):309-320.
-
Zhan X, Xiao H, Wang Q, Luo J, Ma L, Zhang X, Tang J, Meng X. Natural killer cell nano-engagers drive ferroptosis-immunomodulation synergy via inhibition of the Interleukin-6-JAK2-STAT3 Axis. J Control Release. 2026 Feb 10; 390:114581.
-
Qiu J, Alp Y, Gong S, Szipszky P, Jerry DJ, Thayumanavan S. HER2 Antibody-Nanogel Conjugates: A High-Capacity, Antibody-Sparing Alternative to Antibody-Drug Conjugates. Nano Lett. 2026 01 14; 26(1):246-253.
-
Shin JH, Kim JY, Kim SH, Kang Y, Lee HJ, Kim MJ, Choi J, Jeong SK, Park SO, Cho YB, Kim KK, Shim JH, Chun E, Lee KY. USP11 promotes colorectal cancer progression by stabilizing EGFR and TRAF6: a potential therapeutic target in EGFR- and TLR-driven tumorigenesis. Cell Death Dis. 2025 Dec 19; 16(1):894.
-
Giovannoni F, Strathdee CA, Faust Akl C, Andersen BM, Li Z, Lee HG, Torti MF, Rone JM, Duart-Abadia P, Molgora M, Kong L, Floyd M, Teng J, Gyulakian Y, Grzesik P, Farkaly T, Denslow A, Feau S, Rodriguez-Sanchez I, Jacques J, Colonna M, Kennedy EM, Cheema T, Lerner L, Qu?va C, Quintana FJ. Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy. Nat Cancer. 2025 Dec; 6(12):1994-2010.
-
Abu-Remaileh M, Stransky LA, Bhalerao N, Shirole NH, Jiang Q, Saad E, Machaalani M, Vigeant SM, Woldemichael H, Xu C, Lu J, Wei H, Liu Z, Sun W, Enomoto K, Choueiri TK, Pitarresi JR, Carr SA, Udeshi ND, Kaelin WG. Targeting of HIF2-driven cachexia in kidney cancer. Nat Med. 2026 Jan; 32(1):245-257.
-
Shin JH, Kim JY, Kim MJ, Kang Y, Lee HJ, Choi B, Lee JS, Kwon D, Kim SH, Sung Y, Kim DH, Shim JH, Chun E, Lee KY. PYCR1 drives lung cancer progression through functional interactions with EGFR and TLR signaling pathways. Exp Mol Med. 2025 Nov; 57(11):2559-2573.
-
Murphy KC, DeMarco KD, Zhou L, Peura J, Giwa HK, Lopez-Diaz Y, Ho YJ, Li J, Bai S, Simin K, Zhu LJ, Pitarresi JR, Mercurio AM, Ruscetti M. MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. Cancer Res. 2025 Nov 14; 85(22):4359-4379.
-
Luo D, Wang N, Major-Monfried H, Ralls J, Rha S, Maitland SA, Ponnienselvan K, Yamada M, Bauer DE, Wolfe SA, Kentsis A. Modular Platform for Therapeutic Drug Delivery Using Trifunctional Bio-Orthogonal Macromolecular Conjugates. Bioconjug Chem. 2025 Nov 19; 36(11):2472-2486.